185 related articles for article (PubMed ID: 35115195)
1. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Janssen YF; Feitsma EA; Boersma HH; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
Vaccine; 2022 Feb; 40(9):1253-1260. PubMed ID: 35115195
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
[TBL] [Abstract][Full Text] [Related]
3. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Alleva DG; Delpero AR; Scully MM; Murikipudi S; Ragupathy R; Greaves EK; Sathiyaseelan T; Haworth JR; Shah NJ; Rao V; Nagre S; Lancaster TM; Webb SS; Jasa AI; Ronca SE; Green FM; Elyard HA; Yee J; Klein J; Karnes L; Sollie F; Zion TC
Vaccine; 2021 Oct; 39(45):6601-6613. PubMed ID: 34642088
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.
Alleva DG; Feitsma EA; Janssen YF; Boersma HH; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Shaw SA; Aminetzah A; Kruijff S; Brom M; van Dam GM; Zion TC
NPJ Vaccines; 2024 Feb; 9(1):40. PubMed ID: 38383578
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Pérez-Rodríguez S; de la Caridad Rodríguez-González M; Ochoa-Azze R; Climent-Ruiz Y; Alberto González-Delgado C; Paredes-Moreno B; Valenzuela-Silva C; Rodríguez-Noda L; Perez-Nicado R; González-Mugica R; Martínez-Pérez M; Sánchez-Ramírez B; Hernández-García T; Díaz-Machado A; Tamayo-Rodríguez M; Martín-Trujillo A; Rubino-Moreno J; Suárez-Batista A; Dubed-Echevarría M; Teresa Pérez-Guevara M; Amoroto-Roig M; Chappi-Estévez Y; Bergado-Báez G; Pi-Estopiñán F; Chen GW; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V
Vaccine; 2022 Mar; 40(13):2068-2075. PubMed ID: 35164986
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Eugenia-Toledo-Romaní M; Verdecia-Sánchez L; Rodríguez-González M; Rodríguez-Noda L; Valenzuela-Silva C; Paredes-Moreno B; Sánchez-Ramírez B; Pérez-Nicado R; González-Mugica R; Hernández-García T; Bergado-Baez G; Pi-Estopiñán F; Cruz-Sui O; Fraga-Quintero A; García-Montero M; Palenzuela-Díaz A; Baró-Román G; Mendoza-Hernández I; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; Ramírez Gonzalez U; García-Vega Y; Pérez-Massón B; Guang-Wu-Chen ; Boggiano-Ayo T; Ojito-Magaz E; Rivera DG; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V; ; Gómez-Maceo Y; Reyes-Matienzo R; Manuel Coviella-Artime J; Morffi-Cinta I; Martínez-Pérez M; Castillo-Quintana I; Garcés-Hechavarría A; Valera-Fernández R; Martínez-Bedoya D; Garrido-Arteaga R; Cardoso-SanJorge F; Quintero Moreno L; Ontivero-Pino I; Teresa Pérez-Guevara M; Morales-García M; Noa-Romero E; Orosa-Vázquez I; Díaz-Hernández M; Rojas G; Tundidor Y; García-López E; Muñoz-Morejon Y; Galano-Frutos E; Rodríguez-Alvarez J; Arteaga A; Medina Nápoles M; Espi Ávila J; Fontanies Fernández M
Vaccine; 2022 Jul; 40(31):4220-4230. PubMed ID: 35691871
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
11. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
12. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
14. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
16. Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
Martin-Orozco N; Vale N; Mihic A; Amor T; Reiter L; Arita Y; Samson R; Hu Q; Gingras AC; Sorenson BT; Marcusson EG; Patel P
Sci Rep; 2023 May; 13(1):8557. PubMed ID: 37236995
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study.
Tang R; Zeng Y; Zhou Y; Liang Q; Kang W; Yang Z; Zheng X; Zang X; Pan H; Jin J; Zhu F
Expert Rev Vaccines; 2024; 23(1):498-509. PubMed ID: 38695310
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
[TBL] [Abstract][Full Text] [Related]
19. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Sathe N; Shaikh S; Bhavsar M; Parte L; Gadiparthi A; Kad S; Sensarma S; Nalband H; Sangapillai R; Sivashanmuganathan S; Pusalkar R; Anandan S; Masand G; Pratapreddy K; Harinarayana Rao S; Gokhale A; Vidyadhar Reddy GEC; Karanam G; Phatarphekar A; Rao P; Ramana V; Ramnath RL
Vaccine; 2024 Feb; 42(5):1051-1064. PubMed ID: 37816655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
